TY - JOUR
T1 - Prioritizing research challenges and funding for allergy and asthma and the need for translational research—The European Strategic Forum on Allergic Diseases
AU - Agache, Ioana
AU - Annesi-Maesano, Isabella
AU - Bonertz, Andreas
AU - Branca, Francesco
AU - Cant, Andrew
AU - Fras, Zlatko
AU - Ingenrieth, Frank
AU - Namazova-Baranova, Leyla
AU - Odemyr, Mikaela
AU - Spanevello, Antonio
AU - Vieths, Stefan
AU - Yorgancioglu, Arzu
AU - Alvaro-Lozano, Montserat
AU - Barber Hernandez, Domingo
AU - Chivato, Tomás
AU - Del Giacco, Stefano
AU - Diamant, Zuzana
AU - Eguiluz-Gracia, Ibon
AU - van Wijk, Roy Gert
AU - Gevaert, Philippe
AU - Graessel, Anke
AU - Hellings, Peter
AU - Hoffmann-Sommergruber, Karin
AU - Jutel, Marek
AU - Lau, Susanne
AU - Lauerma, Antti
AU - Maria Olaguibel, Jose
AU - O'Mahony, Liam
AU - Ozdemir, Cevdet
AU - Palomares, Oscar
AU - Pfaar, Oliver
AU - Sastre, Joaquin
AU - Scadding, Glennis
AU - Schmidt-Weber, Carsten
AU - Schmid-Grendelmeier, Peter
AU - Shamji, Mohamed
AU - Skypala, Isabel
AU - Spinola, Monica
AU - Spranger, Otto
AU - Torres, Maria
AU - Vereda, Andrea
AU - Bonini, Sergio
N1 - Publisher Copyright:
© 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision-makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy's output with the perspective offered by EAACI's partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real-world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients’ organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics.
AB - The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision-makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy's output with the perspective offered by EAACI's partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real-world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients’ organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics.
KW - allergic diseases
KW - asthma
KW - big data
KW - environmental health
KW - exposome
KW - implementation science
KW - quality criteria
KW - translational research
UR - https://www.scopus.com/pages/publications/85067038591
U2 - 10.1111/all.13856
DO - 10.1111/all.13856
M3 - Article
C2 - 31070805
AN - SCOPUS:85067038591
SN - 0105-4538
VL - 74
SP - 2064
EP - 2076
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 11
ER -